Main Menu

Tetraphase Pharmaceuticals, Inc.



Attention investors who purchased shares of Tetraphase Pharmaceuticals, Inc. before June 4, 2020:

Rigrodsky & Long is investigating potential claims against the board of directors of Tetraphase Pharmaceuticals, Inc. concerning possible breaches of fiduciary duty and other violations of law related to the Company’s agreement to be acquired by Melinta Therapeutics, Inc.

Press Release

Rigrodsky & Long, P.A. announces that it is investigating Tetraphase Pharmaceuticals, Inc. (“Tetraphase”) (NASDAQ GS: TTPH) regarding possible breaches of fiduciary duties and other violations of law related to Tetraphase’s agreement to be acquired Melinta Therapeutics, Inc. (“Melinta”).  Under the terms of the agreement, shareholders of Tetraphase will receive $1.79 in cash for each share of Tetraphase they own, plus a contingent value right (CVR).

If you would like to discuss this investigation and your rights cost and obligation free, please contact Seth D. Rigrodsky or Gina M. Serra toll free at (888) 969-4242 or by e-mail at

Rigrodsky & Long, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising.  Prior results do not guarantee a similar outcome.

Back to Page